Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension by Condliffe, R. et al.
Pulmonary Circulation | January-March 2012 | Vol 2 | No 1 21
Research Ar t ic le
INtRoductIoNPulmonary arterial hypertension (PAH) is a rare, progressive condition characterized by abnormal intimal and medial proliferation within the pulmonary arterial bed[1] resulting in elevation of pulmonary vascular resistance and subsequent right heart failure.[2] Current biomarkers such 
as brain natriuretic peptide (BNP or NT-proBNP) reflect 
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ABSTRACT
We previously reported that osteoprotegerin (OPG) is regulated by pathways associated with pulmonary arterial hypertension 
(PAH), and is present at elevated levels within pulmonary vascular lesions and sera from patients with idiopathic PAH (IPAH). Since 
OPG is a naturally secreted protein, we investigated the relationship between serum OPG and disease severity and outcome in 
patients with IPAH and animal models. OPG mRNA expression was measured in pulmonary artery smooth muscle cells (PASMC) 
from pulmonary arteries of patients with and without IPAH. Serum concentrations of OPG were measured in a retrospective and 
prospective group of patients. OPG levels were compared with phenotypic data and other putative PAH biomarkers. Prognostic 
significance was assessed and levels compared with healthy controls. Correlation of OPG and pulmonary vascular remodeling 
was also performed in rodent models of PAH. OPG mRNA was significantly increased 2-fold in PASMC isolated from explanted 
PAH lungs compared with control. Serum OPG concentrations were markedly elevated in IPAH compared with controls. In Cohort 
1 OPG levels significantly correlated with mean right atrial pressure and cardiac index, while in Cohort 2 significant correlations 
existed between age-adjusted OPG levels and gas transfer. In both cohorts an OPG concentration above a ROC-derived threshold 
of 4728 pg/ml predicted poorer survival. In two rodent models, OPG correlated with the degree of pulmonary vascular remodeling. 
OPG levels are significantly elevated in patients with idiopathic PAH and are of prognostic significance. The role of OPG as a 
potential biomarker and therapeutic target merits further investigation.
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right ventricular load rather than pulmonary arterial remodeling. Subsequently, there has been increased 
interest in identifying biomarkers for PAH that reflects this vasculopathy.Osteoprotegerin (OPG) is a soluble member of the tumor necrosis factor (TNF) receptor family which acts as a decoy 
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receptor for receptor activator of nuclear factor-kB ligand 
(RANKL) in the regulation of osteoclast differentiation. [3] OPG can also block the binding of TNF-related apoptosis-inducing ligand (TRAIL) with its membrane-associated death receptors thus preventing apoptosis.[4] We have previously demonstrated that several molecular pathways previously associated with PAH including reduced bone morphogenetic protein receptor type II (BMPR-2) expression stimulate OPG expression and secretion from pulmonary artery smooth muscle cells (PASMC).[5] Furthermore, we have shown increased protein expression of OPG within remodeled pulmonary vascular lesions and serum from patients with idiopathic PAH (IPAH) compared to controls. Interestingly, elevated levels of OPG have also been observed in PAH associated with congenital systemic to pulmonary shunts.[6] Altered levels and prognostic importance of OPG have been described in systemic cardiovascular disease,[7-10] diabetes[11-13] and connective tissue disease.[14,15] We therefore hypothesized that serum concentrations of OPG would provide meaningful prognostic information in patients with IPAH.
We now report our findings utilizing both an initial retrospective and subsequent prospective collection of patients with IPAH from two separate UK centers. Critically, 
we demonstrated for the first time that OPG mRNA is upregulated in PASMCs isolated from patients with IPAH, suggesting that OPG is produced locally within remodeled 
vessels, and likely contributes significantly to serum levels. 
We also report significant relationships between serum OPG, pulmonary hemodynamics, and survival.
MAtERIAlS ANd MEthodS
oPg gene expression in PASMcRNA was isolated from PASMC grown from explanted pulmonary arteries of three patients with IPAH, and three controls (two emphysema, one lung cancer) as previously described.[16] The RNA was reverse transcribed using Superscript III (Invitrogen, Paisley, UK) and OPG gene expression measured using TaqMan quantitative PCR (Assay ID: Hs00171068_m1, Applied Biosystems, Warrington, UK). The relative quantity of OPG was assessed against 18S ribosomal RNA using the delta-delta comparative CT method.
clinical subjectsSerum samples were obtained from two cohorts of patients with IPAH attending two large designated UK pulmonary vascular disease units. Cohort 1 consisted of 35 patients from Papworth Hospital, Cambridge (28 of whom were prevalent cases on targeted therapy), who were sampled between 2001 and 2006. Cohort 2 (validation cohort) consisted of 23 treatment-naïve incident cases at the 
Royal Hallamshire Hospital, Sheffield, who were sampled during 2009 and 2011. A control group of 35 volunteers 
without PH or significant cardiorespiratory disease were 
age and gender matched for Cohort 2. PAH was defined 
as mean pulmonary arterial pressure (mPAP) ≥25 mmHg in association with a normal pulmonary capillary wedge 
pressure of ≤15 mmHg. Exclusion criteria included associated forms of PAH, FEV1 or FVC <60% predicted, or 
significant parenchymal lung disease on CT imaging. Serum was obtained peripherally in patients in Cohort 1 and at diagnostic right heart catheterization (RHC) in Cohort 2 unless the patient had undergone an isotope perfusion scan on the same day, in which case a peripheral sample was obtained the following day. All samples were obtained, stored, and analyzed in accordance with prior ethical 
approval from North Sheffield Research Ethics Committee 
via the Sheffield NIHR Cardiovascular Biomedical Research Unit Biobank, and Papworth Research Ethics Committee. OPG levels for patients from Cohort 1 have previously been 
reported but not interrogated for prognostic significance.[5]
AnimalsPAH was induced in male Sprague Dawley rats (Charles River, UK) by subcutaneous injection of moncrotaline (Sigma, Poole, UK). Lung harvest was performed at days 2, 7, 14, 21, and 28 postinjection. Male ApoE–/– and ApoE–/– /IL-R1–/– mice 10-12 weeks of age (7 per group) were 
fed Paigen diet for 8 weeks as previously described. [17] 
Where stated disease progression was modified by administration of human IL-1Ra or placebo control (Amgen Inc., Thousand Oaks, Calif, USA. MTA 200517250-001) as previously described.[17] Lungs were harvested at 8 weeks 
and the pulmonary vascular remodeling was quantified as previously described.[17] All animal experiments were 
approved by the University of Sheffield Project Review 
Committee and conformed to UK Home Office ethical guidelines.
oPg measurementOPG concentration in patient[18] and rodent[17] serum was measured using an enzyme-linked immunosorbent assay (ELISA) as previously described.
Statistical analysisBaseline data was described using mean (standard deviation) or median (interquartile range). Comparison between groups was performed using the independent 
t-test and one-way ANOVA with Bonferonni post hoc analysis for parametric data and the Mann–Whitney or Kruskal–Wallis with Dunn’s post hoc analysis tests for nonparametric data. Categorical data were compared with 
the χ2 test. Correlations were assessed using Pearson’s test and multivariate linear regression. Optimal thresholds for 
survival analysis were identified using Receiver-Operated Characteristics (ROC) analysis. Event-free survival (death 
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or lung transplant) was assessed using the Kaplan–Meier method with a census date of July 1, 2009 in Cohort 1 and July 18, 2011 in Cohort 2. A P value of <0.05 was taken as 
significant throughout. Statistical analysis was performed using SPSS 19 (SPSS; Chicago, IL, USA) and GraphPad Prism 5.0d (San Diego, CA, USA) software.
RESultS
oPg mRNA expression is increased in human 
PASMcWe previously showed that OPG protein expression is increased within both concentric and plexiform lesions from patients with IPAH compared to controls.[5] To determine whether de novo synthesis by resident PASMC 
could be the source of this OPG protein, we firstly examined OPG expression in human pulmonary artery smooth muscle cells isolated from patients with IPAH. We found a 
significant 2-fold (P<0.05, Fig. 1) increase in OPG mRNA in un-stimulated PA-SMC from patients with IPAH compared with control PA-SMC isolated from non-PAH explanted lungs. These data suggest that OPG within remodeled lesions can be produced locally, and likely contributes 
significantly to circulating levels. Serum levels of OPG may 
therefore reflect the degree or activity of the underlying pulmonary vascular remodeling.
Patient characteristics, oPg concentrations and 
prognostic strength in a retrospective cohortBaseline demographics and serum OPG concentration for both cohorts and the control are shown in Table 1. The majority (79%) of patients in Cohort 1 were receiving targeted therapy: (24%) bosentan; 6 (17%) epoprostenol; 2 (6%) intravenous iloprost; 2 (6%) nebulized iloprost; 
1 (3%) sildenafil; and 8 (23%) combination therapy at the time of sampling (Table 1). Median serum OPG concentrations in patients with IPAH from Cohort 1 were 
significantly higher than in control (4807 vs. 1352 pg/ml, P<0.001; Fig. 2A). Median time between RHC and serum sampling in Cohort 1 was 2.2 (0.72, 10.5) months. OPG levels correlated positively with mRAP (r=0.37, P=0.03) and inversely with CI (r=-0.36, P=0.04; Table 2). No correlations were observed with age, exercise capacity or WHO functional class nearest to date of sampling. Sixteen patients in Cohort 1 had RHC performed within 90 days of sampling; in these patients OPG concentration correlated positively with mean right atrial pressure (mRAP; r=0.57, P=0.03).Median follow-up from date of sampling to census in Cohort 1 was 3.27 (1.81, 4.26) years. Fourteen patients died during follow-up while four patients underwent lung transplantation. The area under the curve in ROC analysis for the prediction of 4-year event-free survival 
Table 1: Patient demographics and serum concentrations
Cohort 1 Cohort 2 Control
Number 35 23 35
Age (years)* 43.9 (37, 58) 63.6 (48, 71) 58 (51, 72)
Female (%)† 74 61 56
WHO II/III/IV (%)‡ 34/54/12 17/70/13 n/a
mRAP (mmHg) 10.1 (6) 11 (4) n/a
mPAP (mmHg) 54.1 (13) 55.4 (9) n/a
PCWP (mmHg)§ 8.2 (3) 10.4 (3) n/a
CI (l Min m2)¶ 2.0 (0.6) 2.5 (0.8) n/a
PVR (dyn s cm5)** 1163 (341) 883 (417) n/a
OPG (pg/ml)†† 4505  
(2765, 6330)
4807  
(3518, 5866)
1352  
(815, 2021)
FEV1 (%) 80 (14) 85 (13) n/a
FVC (%) 91 (14) 94 (15) n/a
mRAP: Mean right atrial pressure; mPAP: Mean pulmonary artery pressure; 
PCWP: Pulmonary capillary wedge pressure; CI: Cardiac index;  
PVR: Pulmonary vascular resistance; OPG: Osteoprotegerin; FEV1: Forced 
expiratory volume; FVC: Forced vital capacity. Significant pairwise comparisons 
are listed below: *P=0.004 (Cohort 1 vs. Cohort 2); P=0.001 (Cohort 1 vs. 
Control); †P=0.008 (Cohort 1 vs. Control); ‡P=0.02 (Cohort 1 vs. Cohort 2);  
§P=0.017 (Cohort 1 vs. Cohort 2); ¶P=0.006 (Cohort 1 vs. Cohort 2); **P=0.014 
(Cohort 1 vs. Cohort 2); ††P<0.001 (Cohort 1 vs. Control, Cohort 2 vs. Control)
Table 2: Correlations between OPG, exercise capacity, 
TLCO and selected biomarkers
Variable Cohort 1 Cohort 2
r P value R P value
Age -0.10 0.56 0.49 0.019*
6MWD 0.089 0.61 n/a
ISWT n/a -0.34 0.12
mRAP 0.37 0.031* -0.068 0.76
CI -0.36 0.037* -0.17 0.44
DLCO n/a -0.69 0.002*
NT-proBNP n/a 0.085 0.71
eGFR n/a -0.32 0.18
hsCRP n/a 0.33 0.14
IL6 n/a 0.32 0.15
GDF-15 n/a 0.51 0.025*
6MWD: 6-minute walk distance; ISWT: Incremental shuttle walk test; mRAP: 
Mean right atrial pressure; CI: Cardiac index; DLCO: Diffusing capacity for 
Carbon monoxide; NT-proBNP: N-terminal fragment of B-type natriuretic 
peptide; eGFR: Estimated glomerular filtration rate; CRP: High sensitivity C 
reactive protein; IL-6: Interleukin-6; GDF-15: Growth differentiation factor-15. 
*Significant correlation with serum osteoprotegerin; OPG: Osteoprotegerin
Figure 1: OPG mRNA is elevated in PASMC from patients with IPAH. 
Bar graph shows TaqMan derived mRNA expression of OPG in explanted 
PASMC from patients with idiopathic pulmonary arterial hypertension (IPAH) 
and controls, normalised using ΔΔCT with 18S rRNA as the endogenous 
control gene. Bars represent mean±SEM, n=3. **P<0.01 compared to 
control cells.
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by serum OPG concentration was 0.72 with an optimal threshold of 4728 pg/ml (true positive 73%, false positive 
22%). A significant difference in event-free survival was demonstrated using this threshold (3-year survival 85% vs. 40%, P=0.014; Fig. 2B).
Patient characteristics, oPg concentrations and 
prognostic strength in a prospective, treatment-
naïve cohortBaseline demographics and serum OPG concentration for Cohort 2 and controls are shown in Table 1. Patients in Cohort 2 were older, had a higher mean cardiac index (CI) and lower pulmonary vascular resistance than in Cohort 1. All patients were treatment-naïve (Table 1) and all sampling was performed at or within 24 hours of RHC. Median OPG 
concentrations (4505 pg/ml) were significantly higher than 
in controls (1352 pg/ ml, P<0.001; Fig. 3A) while there was 
no significant difference compared with Cohort 1 (4807 
pg/ml, P=ns). In Cohort 2, OPG concentrations correlated positively with age (r=0.49, P=0.019) and inversely with DLCO (r=–0.69, P=0.02; Table 2). When adjusted for age the correlation between OPG and DLCO persisted. No correlations between OPG and pulmonary hemodynamics, exercise capacity or WHO functional class were observed.Median follow-up from date of sampling to census 
in Cohort 2 was 0.62 (0.38, 1.5) years. Patients were treated with targeted therapies in keeping with current 
guidelines. [19] Six patients died during follow-up. The 
previously identified threshold of 4728 pg/ml predicted mortality in Cohort 2 (1 year survival 91% vs. 41%, P=0.046: Fig. 3B). Neither OPG nor traditional important prognostic factors such as pulmonary hemodynamics predicted survival in either Cohort 1 or 2 by univariate Cox regression analysis.
comparison of oPg with previously recognized 
putative biomarkersCorrelations of several previously described putative 
biomarkers were explored in the treatment-naïve Cohort 2. NT-Pro BNP correlated inversely with CI (r=–0.45, P=0.037) and incremental shuttle walking distance (r=–0.52, P=0.016) and positively with mRAP (r=0.53, P=0.011) but not with age, WHO functional class or OPG level. In this 
cohort no threshold of NT-Pro BNP could be identified 
which significantly predicted outcome. No correlations between creatinine, red cell distribution width, GDF-15, 
IL-1β, IL-6, IL-8, IL-10, and IL-12p70 and pulmonary hemodynamics were observed. OPG correlated positively with GDF-15 (r=0.53, P=0.025; Table 2).
Serum oPg correlates with disease progression 
and severity in pre-clinical modelsUtilizing serum and histomorphological data collected from our preclinical animal models, we examined whether there was any correlation between serum OPG and pulmonary vascular remodeling during disease progression and regression. In the monocrotaline rat 
model there was a significant correlation between pulmonary vascular remodeling as assessed by media/cross sectional area (media/CSA) of small pulmonary arterioles (<50 µm) and serum OPG (R2=0.63, P<0.0001; Fig. 4A) over 28 days. We have recently described the 
beneficial effects of treatment with interleukin-1 receptor antagonist (IL-1Ra) in a mouse model of severe pulmonary hypertension that is associated with obliterative pulmonary vascular lesions.[17] To further examine whether OPG would also track with treatment of established disease, we subsequently examined the relationship between serum OPG and media/CSA in these mice and again found 
a significant correlation (R2=0.37, P<0.05: (Fig. 4B)).
Figure 2: Retrospective analysis of serum OPG levels in patients with IPAH. (A) Scatter plot shows serum level of OPG in control and IPAH serum 
(Cohort 1) samples from retrospective analysis of prevalent cases. Dotted line represents the median, n=35. ***P<0.001 compared to control samples. (B) 
Assessment of serum OPG concentration against event-free survival. There was a significantly higher event-free survival in patients with serum OPG concentration 
below 4728 pg/ml (light gray line) having a 3-year survival of 84% compared with vs. 40% in patients with concentrations above 4728 pg/ ml (dark gray line).
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Figure 3: Prospective analysis of serum OPG levels in patients with IPAH. (A) Scatter plot shows serum level of OPG in control and retrospective prevalent 
cases of IPAH (Cohort 1) and prospectively collected samples of treatment naïve incident cases of IPAH (Cohort 2). Dotted line represents the median, n=35 of 
control and Cohort 1, and 23 for Cohort 2. ***P<0.001 compared to control samples. (B) Assessment of serum OPG concentration against event-free survival. 
There was a significantly higher event-free survival in patients with serum OPG concentration below 4728 pg/ml (light gray line) having a 1-year survival of 91% 
compared with vs. 41% in patients with concentrations above 4728 pg/ml (dark gray line).
Figure 4: Serum OPG levels correlate with pulmonary vascular remodeling in rodent models of PAH. Graphs show a significant correlation of serum OPG 
with media/cross-sectional area (Media/CSA) in (A) a time course of disease development in the monocrotaline rat model, and (B) the fat-fed ApoE–/– mouse 
model of PAH with disease regression following treatment with interleukin-1 receptor antagonist (IL-1Ra).
dIScuSSIoNWe previously reported that levels of OPG protein are increased in pulmonary artery lesions and sera from patients with IPAH.[5] Critically, this is the first study to provide evidence that this increased protein expression is driven by resident PASMCs. We subsequently examined the prognostic utility of OPG as a biomarker in both a restrospective and subsequent prospective clinical study. We demonstrated in these two separate cohorts that IPAH 
is characterized by significantly higher serum OPG levels than control patients. We also showed that serum OPG 
correlates significantly with hemodynamic markers of severity such as mRAP and CI in a predominantly prevalent population (Cohort 1), while in an older incident population 
(Cohort 2) there was a significant correlation with DLCO 
even when adjusted for age. Most importantly, we observed that OPG levels >4728 pg/ml predicted poorer survival in both cohorts. In addition we provide further evidence of the utility of OPG as a biomarker for pulmonary vascular 
remodeling by showing a significant correlation between serum levels and vascular remodeling in two animal models of pulmonary hypertension during disease progression but encouragingly, also during regression.
These findings are in keeping with a previous study in which OPG was found to be elevated in patients with PAH associated with congenital systemic to pulmonary shunts[6] and also with several studies which have found OPG to be an important prognostic factor in left 
ventricular disease. [7- 9] Interestingly, in a cohort of patients with acute coronary syndrome, OPG was shown to be of 
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strong prognostic value for mortality and heart failure hospitalization especially in patients with OPG >4540 pg/ml, a very similar level to the prognostic threshold observed in the present study.[20]There is a major unmet need for a marker of pulmonary vascular remodeling. While we cannot rule out a contribution of other sources of OPG in serum, the evidence that PA-SMC express higher levels of OPG mRNA certainly suggests that the remodeling of the distal pulmonary arterial bed during disease progression contributes 
significantly to OPG concentrations in the bloodstream. 
Furthermore, we found significant correlations between serum OPG levels and pulmonary artery remodeling in 2 rodent models. The origin of OPG being in the pulmonary arteries is further supported by the lack of correlation of OPG levels with markers of right ventricular function such as mRAP, CI and NT pro-BNP in Cohort 2. Interestingly we 
also observed a significant correlation between DLCO and OPG. Pulmonary diffusing capacity of carbon monoxide is dependent on the alveolar membrane diffusing capacity and 
pulmonary capillary blood volume. Significantly abnormal 
lung function or a significant degree of parenchymal lung disease were exclusion criteria in the present study and it could therefore be hypothesized that this correlation 
was observed due to high levels of OPG reflecting a higher degree of pulmonary arterial vasculopathy and hence a lower pulmonary capillary blood volume.As has been noted above, however, that elevated OPG levels have been previously observed in left ventricular failure[9] and elsewhere this has been found to occur in both ischemic and non-ischemic forms of cardiomyopathy.[21] It is therefore also possible that a proportion of the serum OPG observed in the present may study arise from the 
right ventricle. This would be supported by the significant correlations observed with both mRAP and CI in Cohort 1.It is interesting to note that there was a difference in observed correlations between OPG and other parameters in the two cohorts. There are several possible explanations for this difference. Firstly, patients in the more recent group 
(Cohort 2) were significantly older than in the earlier group, consistent with the increasing age of patients reported elsewhere.[22] Secondly, the majority of patients in Cohort 1 were already receiving disease-modifying therapies which may have affected OPG levels. A reduction in levels of another chemokine, monocyte chemoattractant protein-1, after treatment with prostacyclin, has previously been observed in patients with IPAH.[23] The effect of disease-modifying therapy on OPG and other chemokines will be assessed in a larger cohort with a longer follow-up. Thirdly, median time between OPG sampling and RHC was 
significant in Cohort 1 while all patients in Cohort 2 had sampling performed either at or within 24 hours of RHC. 
In the present study we also did find correlations between 
previously identified novel biomarkers and pulmonary hemodynamics but it is acknowledged that Cohort 2 is relatively small compared with previous studies.[24]In conclusion, OPG mRNA expression is increased in PA-SMC from patients with IPAH while serum levels are also 
significantly elevated when compared to controls. Levels of OPG >4728 pg/ml are associated with an increased 
chance of death or transplantation. These findings certainly warrant further investigation of OPG as both a biomarker and a potential therapeutic target.
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